CurrentCardio
Get Weekly

Heart failure & cardiomyopathiesSecondary analysis

Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI

JAMA CardiolPublished

  • Secondary analysis of the HELIOS-B randomised trial
  • retrospective post hoc analysis
  • single-centre
  • blinded analysis
  • mixed-model analysis
Read the original article ↗

Authors' conclusion

Results of this selected ATTR-CM cohort study show that treatment with vutrisiran was associated with favorable changes in parameters relating to cardiac structure, function, and amyloid burden.

Study context

Population
Patients with ATTR-CM in the HELIOS-B trial at the UK National Amyloidosis Centre with serial cardiovascular magnetic resonance (CMR) imaging17 at 3-year CMR
Participants
43 patients
Comparison
Vutrisiran vs placebo
  • Vutrisirann = 21
  • Placebon = 22reference
Primary endpoint
Changes in CMR parameters of cardiac structure, volumetrics, function and amyloid burden (ECV)
Follow-up
1, 2 and 3 years

Primary result

As reported in the abstract

CMR parameters, treatment effect (mixed model)
Vutrisiran vs PlaceboLeast-squares mean difference, % (95% CI)P value
LVEF
19.18(11.76%–26.60%)
P < 0.001
RV ejection fraction
16.28(9.58%–22.97%)
P < 0.001
ECV
−6.56(−10.10% to −3.01%)
P < 0.001
Vutrisiran vs PlaceboLeast-squares mean difference, mL (95% CI)P value
LV stroke volume
27.82(13.40–42.23)
P < 0.001
RV stroke volume
23.69(8.06–39.32)
P = 0.003
Vutrisiran vs PlaceboLeast-squares mean difference, g (95% CI)P value
LV mass
−23.58(−38.78 to −8.39)
P = 0.002

Further findings

Amyloid progression (ECV increase ≥5%) · 36 months

OutcomeVutrisiranPlacebo
Amyloid regression (ECV reduction ≥5%) · 36 months22%0 events
  • Amyloid regression (extracellular volume (ECV) reduction ≥5%): 2 of 9 vs 0 of 8
  • Amyloid progression (ECV increase ≥5%): 1 of 9 vs 5 of 8

Original publication

Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI. JAMA Cardiol. Published 12 August 2026. doi:10.1001/jamacardio.2026.2812
Read the original article ↗PubMedCite RIS · BibTeX

Summarised from the published abstract; every number is checked against it